SKIN The Journal of Cutaneous Medicine,
Journal Year:
2020,
Volume and Issue:
4(1), P. 64 - 67
Published: Jan. 28, 2020
Introduction:Checkpoint
inhibitor
immunotherapy
is
associated
with
numerous
adverse
events,
including
eruptive
keratoacanthomas
and
squamous
cell
carcinomas.
However,
no
cases
of
immunotherapy-associated
verrucous
keratoses
(VKs)
have
been
reported.
VKs
are
proliferative
lesions
generally
considered
benign,
although
they
suggested
to
represent
premalignant
lesions.Cases:We
present
the
first
case
series
three
patients
VKs.
The
were
receiving
nivolumab
for
renal
carcinoma,
combination
ipilimumab/nivolumab
non-small
lung
pembrolizumab
malignant
melanoma.
appeared
3-7
months
after
initiation
immunotherapy.
Lesions
treated
shave
removal
or
cryosurgery
without
recurrence.
This
report
adds
spectrum
cutaneous
squamoproliferative
induced
by
checkpoint
JAAD Case Reports,
Journal Year:
2019,
Volume and Issue:
5(4), P. 342 - 345
Published: April 1, 2019
Programmed
cell
death
1
(PD-1)
inhibitors
show
efficacy
in
the
treatment
of
metastatic
melanoma,
non–small
lung
cancer,
urothelial
cancers,
head
and
neck
squamous
carcinoma,
cervical
various
malignancies
with
microsatellite
instability
high
tumor
mutational
burden.
PD-1
are
reported
association
cutaneous
adverse
effects
including
lichenoid
eruption,
eczema,
vitiligo
bullous
pemphigoid.1,2
The
development
keratinocyte
neoplasms
such
as
actinic
keratosis,
seborrheic
basal
carcinoma
have
also
been
reported.
Journal of Cutaneous Pathology,
Journal Year:
2018,
Volume and Issue:
45(6), P. 434 - 438
Published: Feb. 22, 2018
Nivolumab
is
a
fully
human
IgG4
monoclonal
antibody
directed
against
programmed
cell
death
protein
1
(PD-1).
PD-1
inhibition
allows
T-cell
activation
and
recruitment
to
destroy
cancer
cells.
Checkpoint
inhibitors
have
shown
significant
survival
advantage
relatively
low
side-effects
in
comparison
with
conventional
chemotherapy
several
types
of
advanced
cancer.
Granulomatous
cutaneous
reactions
been
reported
showing
sarcoidal
panniculitic
morphology.
Here
we
present
case
drug-induced
lichenoid
granulomatous
dermatitis
after
checkpoint
inhibitor
therapy
observed
63-year-old
male
treated
nivolumab
for
glioblastoma.
This
morphology
has
not
previously
reported.
We
documented
high
number
CD8+
T-cells
within
the
lesions.
Additionally,
review
use
inhibitors,
special
focus
on
manifestations.
Cutis,
Journal Year:
2023,
Volume and Issue:
111(5)
Published: May 1, 2023
POINTS•
Eruptive
keratoacanthomas
(KAs)
are
a
rare
but
transient
adverse
effect
of
programmed
cell
death
protein
1
(PD-1)
inhibitor
therapy.•
Nivolumab,
human
monoclonal
IgG4
antibody,
is
used
as
an
antitumor
treatment
for
melanoma
by
blocking
PD-1.•
Possible
new
treatments
may
hasten
the
regression
eruptive
KAs,
which
could
allow
patients
to
continue
PD-1
therapy.
